These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34141776)

  • 21. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome.
    Boppidi H; Daram SR
    Postgrad Med; 2008 Jul; 120(2):E01-7. PubMed ID: 18654060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
    Dietrich P; Hellerbrand C
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19: a conundrum to decipher.
    Deshmukh V; Tripathi SC; Pandey A; Deshmukh V; Vykoukal J; Patil A; Sontakke B
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5830-5841. PubMed ID: 32495923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic fatty liver disease as a multi-systemic disease.
    Fotbolcu H; Zorlu E
    World J Gastroenterol; 2016 Apr; 22(16):4079-90. PubMed ID: 27122660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective.
    Ching-Yeung Yu B; Kwok D; Wong VW
    J Clin Exp Hepatol; 2019; 9(4):491-496. PubMed ID: 31516265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    Fan JG; Saibara T; Chitturi S; Kim BI; Sung JJ; Chutaputti A;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first?
    Ahmed MH; Ali A
    Scand J Gastroenterol; 2014 May; 49(5):521-7. PubMed ID: 24646400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases.
    Cai J; Zhang XJ; Ji YX; Zhang P; She ZG; Li H
    Circ Res; 2020 Feb; 126(5):679-704. PubMed ID: 32105577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
    Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
    Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 and the liver: What do we know so far?
    Nasa P; Alexander G
    World J Hepatol; 2021 May; 13(5):522-532. PubMed ID: 34131467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD).
    Duseja A; Chalasani N
    Hepatol Int; 2013 Dec; 7 Suppl 2():755-64. PubMed ID: 26202291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
    Younossi ZM; Koenig AB; Abdelatif D; Fazel Y; Henry L; Wymer M
    Hepatology; 2016 Jul; 64(1):73-84. PubMed ID: 26707365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications.
    Selvakumar PKC; Kabbany MN; Nobili V; Alkhouri N
    Pediatr Clin North Am; 2017 Jun; 64(3):659-675. PubMed ID: 28502444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis.
    Arulanandan A; Ang B; Bettencourt R; Hooker J; Behling C; Lin GY; Valasek MA; Ix JH; Schnabl B; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1513-20.e1. PubMed ID: 25661453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
    Zhu C; Zhou D; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polycystic ovary syndrome: Pathways and mechanisms for possible increased susceptibility to COVID-19.
    Ilias I; Goulas S; Zabuliene L
    World J Clin Cases; 2021 Apr; 9(12):2711-2720. PubMed ID: 33969054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease.
    Targher G; Byrne CD
    Metab Syndr Relat Disord; 2015 Aug; 13(6):235-8. PubMed ID: 25714786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
    Akyuz U; Yesil A; Yilmaz Y
    Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.